46
Participants
Start Date
May 31, 2008
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
Docetaxel
Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
Epirubicin
Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
Bevacizumab
Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli
"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens
"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens
"Marika Iliadis Hospital of Athens, Dep of Medical Oncology", Athens
401 Military Hospital of Athens, Athens
Air Forces Military Hospital of Athens, Athens
University Hospital of Crete, Dep of Medical Oncology, Heraklion
State General Hospital of Larissa, Dep of Medical Oncology, Larissa
"Metaxa's Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology", Piraeus
"Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology", Thessaloniki
Lead Sponsor
Hellenic Oncology Research Group
OTHER